Tosha Johnson
Nurse Practitioner · Nampa, IDNPI 1639214216
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (39.7%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Actelion Pharmaceuticals US, Inc. accounts for 70.2% of it on its own, with 22 other manufacturers making up the rest. Reporting peaked in 2022 at $12,010 and has fallen 87.9% since, to $1,451 in 2025. Among nurse practitioner clinicians in ID with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 257 payments — averaging $100.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Actelion Pharmaceuticals US, Inc.$18K
- Abbott$2K
- Medtronic$1K
- E.r. Squibb & Sons, L.L.C.$1K
- Amgen$459
- Pfizer$327
- plus $2K from 17 others
What the payments were for
- Consulting fees$3,74815%
- Speaking & faculty fees$10,22040%
- Travel & lodging$5,02920%
- Food & beverage$6,58126%
- Education$1731%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Actelion Pharmaceuticals US, Inc. | 90 | $18,070 |
| Abbott | 26 | $2,449 |
| Medtronic | 19 | $1,451 |
| E.r. Squibb & Sons, L.L.C. | 18 | $1,105 |
| Amgen | 17 | $459 |
| Pfizer | 16 | $327 |
| AstraZeneca | 11 | $265 |
| Novartis | 15 | $264 |
| Abiomed | 3 | $206 |
| Bayer | 8 | $176 |
| Alnylam Pharmaceuticals Inc. | 4 | $166 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $159 |
| Irhythm Technologies, Inc. | 5 | $152 |
| Merck | 2 | $91 |
| AbbVie | 1 | $87 |
| Biotronik Inc. | 4 | $83 |
| Johnson & Johnson | 5 | $75 |
| Edwards Lifesciences | 2 | $59 |
| United Therapeutics Corporation | 4 | $44 |
| Esperion Therapeutics, Inc. | 1 | $18 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $17 |
| Sandoz | 1 | $17 |
| Preventice Services, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$25,752 in reported general payments places this provider in the 95th percentile of 570 nurse practitioner providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OpsumitMacitentan | 12 | $154,407 |
| EliquisApixaban | 71 | $80,548 |
| FarxigaDapagliflozin Propanediol | 22 | $22,442 |
| XareltoRivaroxaban | 14 | $20,257 |
| EntrestoSacubitril/Valsartan | 12 | $15,636 |
| Metoprolol Succinate | 63 | $823 |
| SotalolSotalol Hcl | 20 | $474 |
| ClopidogrelClopidogrel Bisulfate | 34 | $358 |
| Atorvastatin Calcium | 25 | $283 |
| Losartan Potassium | 29 | $279 |
| Rosuvastatin Calcium | 23 | $246 |
| Potassium Chloride | 12 | $241 |
| Torsemide | 13 | $153 |
| Lisinopril | 22 | $151 |
| Amlodipine Besylate | 26 | $140 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Opsumit | $18,070 | $154,40712 claims |
| PfizerEliquis | $327 | $80,54871 claims |
| AstraZenecaFarxiga | $265 | $22,44222 claims |
| Johnson & JohnsonXarelto | $75 | $20,25714 claims |
| NovartisEntresto | $264 | $15,63612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 570 nurse practitioner providers in Idaho.
Other nurse practitioner in Nampa
- Holly SwensenNampa$5K
- Kathleen CliffordBoise$119K
- Alissa HelvikCoeur D Alene$93K
- Amanda ThompsonIdaho Falls$67K
- Micalena PerkinsBurley$44K
- Loreen NugentBoise$20K
- Rachel RyanMeridian$19K
- Stephanie HartPost Falls$18K
- Joshua ScovilleTwin Falls$12K
- John PilcherBoise$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.